Bioactivation of the human carcinogen aristolochic acid

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages 1814-1822

  Sidorenko, Viktoriya S ^a   Attaluri, Sivaprasad ^a   Zaitseva, Irina ^a   Iden, Charles R ^a   Dickman, Kathleen ^a   Johnson, Francis ^a   Grollman, Arthur P ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Aristolochic acid; Bioactivation; DNA adduct; N hydroxyaristolactam; Sulfonation; Sulfotransferase

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; ARISTOLACTAM DNA; ARISTOLACTAM I N ACETOXY ESTER; ARISTOLOCHIC ACID; ARISTOLOLACTAM; CARCINOGEN; CELL PROTEIN; DNA; N HYDROXYARISTOLACTAM I; N HYDROXYARISTOLACTAM II; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1B1; UNCLASSIFIED DRUG; 3'-PHOSPHOADENYLYL-5'-PHOSPHOSULFATE REDUCTASE; ARISTOLOCHIC ACID I; ARYL SULFOTRANSFERASE; DNA ADDUCT; ETHANOLAMINE DERIVATIVE; IODOTHYRONINE SULFOTRANSFERASE; MONOAMINE-SULFATING PHENOL SULFOTRANSFERASE; N-STEAROYLETHANOLAMINE; NQO1 PROTEIN, HUMAN; OXIDOREDUCTASE; STEARIC ACID DERIVATIVE; SULT1A1 PROTEIN, HUMAN; SULT1A2 PROTEIN, HUMAN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CARCINOGENIC ACTIVITY; COMPARATIVE STUDY; CYTOSOL; CYTOSOLIC FRACTION; DNA ADDUCT; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER CYTOSOL; MALE; METABOLIC ACTIVATION; MOUSE; NEGATIVE ION ELECTROSPRAY; NONHUMAN; POST LABELING PHOSPHORUS 32; PRIORITY JOURNAL; REDUCTION; TIME OF FLIGHT MASS SPECTROMETRY; ANIMAL; C3H MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; KIDNEY; LIVER; MASS SPECTROMETRY; METABOLISM; WESTERN BLOTTING;

ANIMALS; ARISTOLOCHIC ACIDS; ARYLSULFOTRANSFERASE; BLOTTING, WESTERN; CARCINOGENS; CELL PROLIFERATION; CELLS, CULTURED; CYTOSOL; DNA ADDUCTS; ETHANOLAMINES; FIBROBLASTS; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C3H; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAD(P)H DEHYDROGENASE (QUINONE); OXIDOREDUCTASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STEARIC ACIDS; SULFOTRANSFERASES;

EID: 84904671386     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu095     Document Type: Article

References (55)

1. Debelle, F.D., et al. (2008) Aristolochic acid nephropathyworldwide problem. Kidney Int, 74, 158-69.
2. Vanherweghem, J.L., et al. (1993) Rapidly progressive interstitial renal fibrosis in young women: ssociation with slimming regimen including Chinese herbs. Lancet, 341, 387-91.
3. Jelakovic, B., et al. (2012) Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int, 81, 559-67.
4. Grollman, A.P., et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A, 104, 12129-34.
5. (2011) NTP 12th Report on Carcinogens. Rep Carcinog, 45-49.
6. Nortier, J.L., et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med, 342, 1686-92.
7. Kumar, V., et al. (2003) Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat Prod Rep, 20, 565-83.
8. Shibutani, S., et al. (2007) Selective toxicity of aristolochic acids I and II. Drug Metab Dispos, 35, 1217-22.
9. Sato, N., et al. (2004) Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol, 56, 221-9.
10. Pfau, W., et al. (1990) Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis, 11, 313-9.
11. Schmeiser, H.H., et al. (1991) Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett, 59, 139-43.
12. Attaluri, S., et al. (2010) DNA adducts of aristolochic acid II: total synthesis and sitespecific mutagenesis studies in mammalian cells. Nucleic Acids Res, 38, 339-52.
13. Schmeiser, H.H., et al. (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res, 56, 2025-8.
14. Chen, C.H., et al. (2012) Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A, 109, 8241-6.
15. Pfau, W., et al. (1990) The structural basis for the mutagenicity of aristolochic acid. Cancer Lett, 55, 7-11.
16. Purohit, V., et al. (2000) Mutagenicity of nitroaromatic compounds. Chem Res Toxicol, 13, 673-92.
17. Arlt, V.M., et al. (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res, 65, 2644-52.
18. Stiborova, M., et al. (2009) The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 153, 5-11.
19. Levova, K., et al. (2012) NAD(P)H:quinone oxidoreductase expression in Cyp1aknockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I. Toxicol Appl Pharmacol, 265, 360-7.
20. Chen, M., et al. (2011) Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci, 122, 288-96.
21. Blanchard, R.L., et al. (2004) A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics, 14, 199-211.
22. Freimuth, R.R., et al. (2004) Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes. Pharmacogenomics J, 4, 54-65.
23. Blum, M., et al. (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol, 9, 193-203.
24. Meinl, W., et al. (2006) Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer, 118, 1090-7.
25. Stiborova, M., et al. (2011) The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen, 52, 448-59.
26. O'Neil, M.J., et al. (2006) An Encyclopedia of Chemicals, Drugs and Biologicals. Whitehouse Station, NJ.
27. Sidorenko, V.S., et al. (2012) Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res, 40, 2494-505.
28. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
29. Shibutani, S., et al. (2006) 32P-postlabeling DNA damage assays: PAGE, TLC, and HPLC. Methods Mol Biol, 314, 307-21.
30. Gamage, N.U., et al. (2003) Structure of a human carcinogen-converting enzyme, SULT1A1. Structural and kinetic implications of substrate inhibition. J Biol Chem, 278, 7655-62.
31. Martinek, V., et al. (2011) Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro Endocrinol Lett, 32 Suppl 1, 57-70.
32. Boelsterli, U.A., et al. (2006) Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab, 7, 715-27.
33. Glatt, H. (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact, 129, 141-70.
34. Hein, D.W., et al. (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis, 14, 1633-8.
35. Chan, W., et al. (2007) Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab Dispos, 35, 866-74.
36. Dooley, T.P., et al. (2000) Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem Biophys Res Commun, 277, 236-45.
37. Krumbiegel, G., et al. (1987) Studies on the metabolism of aristolochic acids I and II. Xenobiotica, 17, 981-91.
38. Rosenquist, T.A., et al. (2010) Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos, 38, 761-8.
39. Riches, Z., et al. (2009) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT pie. Drug Metab Dispos, 37, 2255-61.
40. Teubner, W., et al. (2007) Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J, 404, 207-15.
41. Senggunprai, L., et al. (2008) Involvement of ST1B subfamily of cytosolic sulfotransferase in kynurenine metabolism to form natriuretic xanthurenic acid sulfate. J Pharmacol Exp Ther, 327, 789-98.
42. Hein, D.W. (1988) Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta, 948, 37-66.
43. Husain, A., et al. (2007) Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos, 35, 721-7.
44. McQueen, C.A., et al. (2003) Neonatal ontogeny of murine arylamine Nacetyltransferases: implications for arylamine genotoxicity. Toxicol Sci, 73, 279-86.
45. Oda, Y., et al. (2012) Roles of human sulfotransferases in genotoxicity of carcinogens using genetically engineered umu test strains. Environ Mol Mutagen, 53, 152-64.
46. Hoang, M.L., et al. (2013) Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med, 5, 197ra102.
47. Ma, L., Kuhlow, A., Glatt, HR. (2003) Albumin strongly prolongs the lifetime of chemically reactive sulphuric esters and affects their biological activities in the rat. Nova Acta Leopoldina, 329, 265-272.
48. Monien, B.H., et al. (2009) Probenecid, an inhibitor of transmembrane organic anion transporters, alters tissue distribution of DNA adducts in 1-hydroxymethylpyrene-treated rats. Toxicology, 262, 80-5.
49. Bakhiya, N., et al. (2006) Uptake of chemically reactive, DNA-damaging sulfuric acid esters into renal cells by human organic anion transporters. J Am Soc Nephrol, 17, 1414-1421.
50. Jiang, Y., et al. (2010) Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue. J Exp Clin Cancer Res, 29, 101.
51. Hirata, H., et al. (2008) CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73.
52. Roupret, M., et al. (2007) Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. Cancer Epidemiol Biomarkers Prev, 16, 2500-3.
53. Ung, D., et al. (2007) Variable sulfation of dietary polyphenols by recombinant human sulfotransferase (SULT) 1A1 genetic variants and SULT1E1. Drug Metab Dispos, 35, 740-6.
54. Priestap, H.A., et al. (2012) Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol, 25, 130-9.
55. Hildebrandt, M.A., et al. (2007) Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J, 7, 133-43.